Stephen V Liu/X
Feb 4, 2025, 10:31
Stephen V Liu: The Phase 2b REZILIENT1 study of zipalertinib met its primary endpoint
Stephen V Liu, Associate Professor of Medicine at Georgetown University, Director of Thoracic Oncology and Head of Developmental Therapeutics at the Georgetown Lombardi Comprehensive Cancer Center, shared a post on X:
“The Phase 2b REZILIENT1 study of zipalertinib (CLN-081/TAS6417) met its primary endpoint of response rate in patients with EGFR exon 20 insertion mutation NSCLC.”
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Feb 4, 2025, 10:34
Feb 4, 2025, 09:59
Feb 4, 2025, 09:55
Feb 4, 2025, 09:34
Feb 4, 2025, 09:30
Feb 4, 2025, 09:23
Feb 4, 2025, 09:13
Feb 4, 2025, 09:09
Feb 4, 2025, 09:04